Publication

Effect of progression-free interval (pfi) following penultimate platinum-based regimen on the efficacy of rucaparib maintenance treatment in patients with platinum-sensitive, recurrent ovarian carcinoma: an analysis from the phase 3 study ARIEL3

Clamp, Andrew R
; 
Oza, AM
; 
Lorusso, D
; 
Aghajanian, C
; 
Oaknin, A
; 
Dean, A
; 
Colombo, N
; 
Weberpals, JI
; 
Scambia, G
; 
Leary, A
... show 10 more
Citations
Altmetric:
Abstract
Authors
Clamp, Andrew R
Oza, AM
Lorusso, D
Aghajanian, C
Oaknin, A
Dean, A
Colombo, N
Weberpals, JI
Scambia, G
Leary, A
Holloway, RW
Gancedo, MA
Fong, PC
Goh, IC
O'Malley, DM
Armstrong, DK
Banerjee, S
Garcia-Donas, J
Swisher, EM
Cameron, T
Maloney, L
Goble, S
Coleman, RL
Ledermann, JA
Affiliation
Department of Medical Oncology, The Christie NHS Foundation Trust and University of Manchester, Manchester
Description
Date
2019
Publisher
Collections
All Christie Publications
Show all metadata
Keywords
Type
Article
Citation
Clamp AR, Oza AM, Lorusso D, Aghajanian C, Oaknin A, Dean A, et al. Effect of progression-free interval (PFI) following penultimate platinum-based regimen on the efficacy of rucaparib maintenance treatment in patients with platinum-sensitive, recurrent ovarian carcinoma: an analysis from the phase 3 study ARIEL3. International Journal of Gynecological Cancer. 2019;29:A27-A8.
Journal Title
Journal ISSN
Volume Title
URI
http://hdl.handle.net/10541/622954
Embedded videos